180 Life Sciences Corp.
NASDAQ Capital Market•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Sir Marc Feldmann Ph.D.
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Building 4 Palo Alto CA United States of America 94306
- IPO Date
- Jun 27, 2017
- CIK
- 0001690080
- Website
- 180lifesciences.com
- Similar Companies
- Business
- 1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Company News
180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors
180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform
180 Life Sciences Corp. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule and Expands into the Global iGaming Sector
180 Life Sciences Corp. - Corporate Updates
180 Life Sciences Announces the Appointment of Omar Jimenez as Chief Financial Officer
180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake
180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan
180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives
180 Life Sciences Announces Review of Strategic Alternatives
180 Life Sciences Corp. Announces Closing of $3 Million Public Offering
180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering
Why Is 180 Life Sciences (ATNF) Stock Up 38% Today?
180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake
Penny Stock Investing, 3 High-Growth Industries to Watch
5 Top Penny Stocks To Watch Today; Time To Buy?
Elicit Plant beruft Pam Marrone und Johan de Saegher in den Vorstand
Elicit Plant Appoints Pam Marrone and Johan de Saegher on Its Board of Directors
Elicit Plant nomme Pam Marrone et Johan de Saegher à son Conseil d’administration